National Institutes of Health: Lymphoma, Mantle-Cell trials

The registry lists 85 Lymphoma, Mantle-Cell studies with National Institutes of Health as lead sponsor. 3 are open to participants now and 24 have results posted.

Early Phase 1 1Phase 1 53Phase 2 36No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventEnrolling by invitationNCT07499128Not applicable
• Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingNCT07003295Phase 2
• Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxRecruitingNCT05724121
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLTerminatedNCT02572453Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaCompletedNCT01381692Phase 1/2Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedNCT00445341Phase 1/2Results posted
• Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell LymphomaCompletedNCT00433537Phase 2Results posted
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00383565Phase 2Results posted
• Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
• Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCompletedNCT00253630Phase 2Results posted
• 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's LymphomaCompletedNCT00117988Phase 2Results posted
• EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
• MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
• Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 2Results posted
• Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00058019Phase 2Results posted
• Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
• Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
• Chemotherapy Plus Vaccination to Treat Mantle Cell LymphomaCompletedNCT00005780Phase 2Results posted
• Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersCompletedNCT01117142
• Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
• FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
• Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00278382Phase 2
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00033267Phase 2
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaCompletedNCT00018954Phase 2
• Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00017381Early Phase 1
• S0108 Bevacizumab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00016094Phase 2
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00003039Phase 2